Novo Nordisk Issues Mixed 2026 Outlook with Adjusted Sales/Profit Decline Amidst Pricing Pressures

summarizeSummary

Novo Nordisk provided its 2026 financial outlook, projecting a decline in adjusted sales and operating profit due to pricing pressures and competition, despite a significant one-time $4.2 billion rebate reversal boosting non-adjusted figures.

check_boxKey Events

• 2026 Outlook Released

  Novo Nordisk provided its full-year 2026 sales and operating profit outlook, following 10% sales growth and 6% operating profit growth in 2025.

• New Adjusted Metrics Introduced

  The company will now report 'adjusted sales growth' and 'adjusted operating profit growth' to exclude exceptional and non-recurring items, enhancing transparency of underlying performance.

• Adjusted Outlook Projects Decline

  Adjusted sales and operating profit are projected to decline by -5% to -13% at constant exchange rates for 2026.

• Significant One-Time Gain

  A $4.2 billion reversal of sales rebate provisions related to the 340B Drug Pricing Program will positively impact non-adjusted 2026 results, leading to a non-adjusted operating profit growth mid-point of 11%.

auto_awesomeAnalysis

Novo Nordisk's 2026 outlook presents a complex picture for investors. While the company anticipates an 11% increase in non-adjusted operating profit, this is largely driven by a one-time $4.2 billion reversal of sales rebate provisions related to the 340B Drug Pricing Program. More critically, the newly introduced "adjusted" metrics, which exclude such non-recurring items, project a significant decline of -5% to -13% for both sales and operating profit. This adjusted outlook highlights underlying challenges including lower realized prices due to the MFN agreement in the US, intensifying competition in the GLP-1 market, and loss of exclusivity for semaglutide in certain international markets. Investors will need to carefully consider these adjusted figures as a more accurate reflection of the company's ongoing operational performance, despite continued GLP-1 market expansion and new product launches like the Wegovy pill.